Clinical Trials Browser

Phase 2 × Lymphoma × Nuclear Medicine Department, Hospital × Clear all

NCT06385483 2026-03-19

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Phase 2 Active not recruiting

19 enrolled 10 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT06390826 2026-03-17

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

Phase 2 Active not recruiting

10 enrolled 10 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT04320888 2025-12-04

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Phase 2 Active not recruiting

1 enrolled 3 charts

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT06357988 2025-10-20

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

Phase 2 Active not recruiting

35 enrolled

LymphoidPlasma cell

Lymphoma, Multiple Myeloma